Santhera 的授权合作伙伴 Nxera Pharma 在韩国提交 AGAMREE® (Vamorolone) 上市许可申请

Santhera Pharmaceuticals' licensing partner, Nxera Pharma, has formally submitted a Marketing Authorization Application to South Korea's Ministry of Food and Drug Safety. The regulatory filing seeks approval for AGAMREE, internationally known as vamorolone, as a novel treatment option for patients in the region. This submission represents a crucial step in Santhera's broader strategy to expand the global commercial footprint of its flagship pharmaceutical asset through trusted regional partnerships. South Korean health authorities will now begin their formal review process to evaluate the drug's efficacy, safety, and manufacturing quality. Successful approval would unlock a new geographic market and provide a vital therapeutic alternative for patients suffering from the targeted condition. Both companies anticipate a thorough review period as they prepare commercialization strategies for the Asian market.